Bio-Techne (NASDAQ:TECH) Posts Quarterly Earnings Results, Hits Estimates

Bio-Techne (NASDAQ:TECH) announced its earnings results on Wednesday. The biotechnology company reported $0.52 EPS for the quarter, meeting analysts’ consensus estimates of $0.52, FiscalAI reports. Bio-Techne had a return on equity of 13.57% and a net margin of 9.05%.The company had revenue of $321.19 million during the quarter, compared to the consensus estimate of $314.63 million. During the same quarter in the prior year, the company earned $0.53 earnings per share. The firm’s revenue for the quarter was up 1.3% on a year-over-year basis.

Bio-Techne Price Performance

Shares of TECH opened at $72.23 on Thursday. Bio-Techne has a fifty-two week low of $43.19 and a fifty-two week high of $72.39. The firm’s 50-day simple moving average is $66.61 and its two-hundred day simple moving average is $59.19. The stock has a market cap of $11.31 billion, a PE ratio of 104.68, a price-to-earnings-growth ratio of 8.59 and a beta of 1.28. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.18 and a current ratio of 4.49.

Bio-Techne Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 24th. Shareholders of record on Friday, September 4th will be issued a $0.65 dividend. This represents a $2.60 dividend on an annualized basis and a yield of 3.6%. This is a boost from Bio-Techne’s previous quarterly dividend of $0.08. The ex-dividend date is Friday, September 4th. Bio-Techne’s dividend payout ratio is currently 46.38%.

Key Headlines Impacting Bio-Techne

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Bio-Techne reported fiscal Q4 revenue of approximately $321.2 million, ahead of the $314.7 million analyst consensus. Organic revenue increased 3%, supported by demand in the research and diagnostics businesses. Bio-Techne beats revenue estimates on research, diagnostics demand uptick
• Positive Sentiment: Adjusted earnings were $0.52 per share, in line with expectations, while revenue rose 1.3% year over year. Profitability improved substantially on a GAAP basis, with quarterly net income of $54.6 million versus a $17.7 million loss a year earlier. Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
• Positive Sentiment: The company declared a quarterly dividend of $0.08 per share, payable August 28 to shareholders of record August 17. The dividend provides a modest shareholder return and signals continued balance-sheet support. Bio-Techne Declares Dividend
• Positive Sentiment: Bio-Techne’s agreed acquisition by Merck KGaA for $73 per share in cash gives investors a defined transaction value and helps explain why the stock is trading near its 52-week high.
• Neutral Sentiment: Fiscal 2026 revenue was approximately $1.2 billion, essentially flat from the prior year. Adjusted EPS also declined slightly from $0.53 to $0.52, indicating limited underlying growth despite the quarterly revenue beat.
• Negative Sentiment: With shares near Merck’s $73-per-share offer, the remaining standalone upside appears limited and the stock remains exposed to deal-completion risk. Bio-Techne also said it will stop holding quarterly investor conference calls following the acquisition agreement, reducing near-term management updates.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TECH. Robert W. Baird boosted their price objective on shares of Bio-Techne from $49.00 to $73.00 and gave the company a “neutral” rating in a research report on Friday, June 26th. Evercore cut shares of Bio-Techne from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Stifel Nicolaus set a $50.00 target price on shares of Bio-Techne in a research note on Thursday, May 7th. Stephens set a $73.00 price target on shares of Bio-Techne and gave the stock an “equal weight” rating in a research note on Friday, June 26th. Finally, Citigroup downgraded Bio-Techne from a “buy” rating to a “neutral” rating and upped their target price for the stock from $70.00 to $73.00 in a report on Friday, June 26th. Three research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $68.08.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TECH. Alberta Investment Management Corp bought a new position in shares of Bio-Techne during the fourth quarter valued at $1,300,000. Wellington Management Group LLP boosted its stake in Bio-Techne by 12.1% in the 4th quarter. Wellington Management Group LLP now owns 5,734,049 shares of the biotechnology company’s stock worth $337,219,000 after purchasing an additional 618,916 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its position in Bio-Techne by 20.8% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 118,799 shares of the biotechnology company’s stock valued at $6,987,000 after purchasing an additional 20,423 shares during the last quarter. AQR Capital Management LLC grew its position in Bio-Techne by 42.1% during the 4th quarter. AQR Capital Management LLC now owns 26,087 shares of the biotechnology company’s stock valued at $1,534,000 after purchasing an additional 7,733 shares during the last quarter. Finally, Laird Norton Wetherby Trust Company LLC bought a new stake in Bio-Techne during the 4th quarter valued at about $468,000. Institutional investors own 98.95% of the company’s stock.

Bio-Techne Company Profile

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.